An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 189 participants.
Also called NCT05562934
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 189 participants
- Sponsor
- Registry
-
NCT05562934 -
2021-005738-41
-
- Other papers using this trial's data
- Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension: A Randomized Phase 2 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Bulgaria, China, Czechia, France, Germany, Italy, Japan, Netherlands, Poland, Slovakia, Spain, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05562934. Randomized; triple masking; primary purpose treatment. Start 2022-11-08 (actual); primary completion 2024-07-02 (actual). Results posted on 2025-10-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
- Condition
- Resistant Hypertension
- Intervention (Biological)
- XXB750 drug
- Intervention (Other)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05562934- Content hash
478c4427e16495cd97536b25ec9f371c6804503d9e717d5f028a8d43ec7fdf4d